At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02367 GIANT BIOGENE
Trading 09-01 09:51:53
26.200
+0.440
+1.71%
High26.220Low25.580Vol321.80K
Open25.800D1 Closing25.760Amplitude2.48%
Mkt Cap27.82BTradable Cap27.82BTotal Shares1.06B
T/O8.34MT/O Rate0.03%Tradable Shares1.06B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Hong Kong Stock Alert | GIANT BIOGENE (02367) Drops Over 6% Again as Company Voluntarily Restructures Channel Mix, Pressuring H1 Performance
Stock News  ·  08-21
Hong Kong Stock Alert | GIANT BIOGENE (02367) Drops Over 6% Again as Company Voluntarily Restructures Channel Mix, Pressuring H1 Performance
Movement Alert｜GIANT BIOGENE Declines 5.14% in Regular Trading, China Merchants Securities Downgrades to Sell with HK$25 Target Price
Market Focus  ·  08-21
Movement Alert｜GIANT BIOGENE Declines 5.14% in Regular Trading, China Merchants Securities Downgrades to Sell with HK$25 Target Price
The Giant Biogene Holding Co., Ltd. (HKG:2367) Half-Year Results Are Out And Analysts Have Published New Forecasts
Simply Wall St.  ·  08-21
The Giant Biogene Holding Co., Ltd. (HKG:2367) Half-Year Results Are Out And Analysts Have Published New Forecasts
China Merchants Securities Downgrades Giant Biogene to Sell from Hold; Price Target is HK$25
MT Newswires Live  ·  08-20
China Merchants Securities Downgrades Giant Biogene to Sell from Hold; Price Target is HK$25
Movement Alert｜GIANT BIOGENE Rises 5.7% in Regular Trading, Multiple Brokerages Maintain Buy Ratings Post-Earnings Boosting Sentiment
Market Focus  ·  08-20
Movement Alert｜GIANT BIOGENE Rises 5.7% in Regular Trading, Multiple Brokerages Maintain Buy Ratings Post-Earnings Boosting Sentiment
Giant Biogene Holding (SEHK:2367) Stock Confronts Margin Squeeze After Profit Pullback
Simply Wall St.  ·  08-19
Giant Biogene Holding (SEHK:2367) Stock Confronts Margin Squeeze After Profit Pullback
Rising Marketing Costs Squeeze Giant Biogene's Margins in Latest Half-Year Results
Deep News  ·  08-19
Rising Marketing Costs Squeeze Giant Biogene's Margins in Latest Half-Year Results
Citi Raises GIANT BIOGENE Price Target to HK$38.4, Citing Strong Recovery Visibility
Stock News  ·  08-19
Citi Raises GIANT BIOGENE Price Target to HK$38.4, Citing Strong Recovery Visibility
Hong Kong Stock Flash | GIANT BIOGENE (02367) Drops Nearly 7% Post-Earnings as Company Voluntarily Adjusts Sales Mix, H1 Net Profit Down Over 20%
Stock News  ·  08-19
Hong Kong Stock Flash | GIANT BIOGENE (02367) Drops Nearly 7% Post-Earnings as Company Voluntarily Adjusts Sales Mix, H1 Net Profit Down Over 20%
Movement Alert｜GIANT BIOGENE Falls 5.48% in Regular Trading, Interim Results Show Revenue and Net Profit Both Decline
Market Focus  ·  08-19
Movement Alert｜GIANT BIOGENE Falls 5.48% in Regular Trading, Interim Results Show Revenue and Net Profit Both Decline
Giant Biogene's Profit Drops on Higher Distribution Expenses
Reuters  ·  08-18
Giant Biogene's Profit Drops on Higher Distribution Expenses
Giant Biogene FY26 H1 Net Profit Drops 20.5% to RMB 939.5 Million; Revenue Falls 6.3% to RMB 2.92 Billion
Reuters  ·  08-18
Giant Biogene FY26 H1 Net Profit Drops 20.5% to RMB 939.5 Million; Revenue Falls 6.3% to RMB 2.92 Billion
Giant Biogene Holding H1 Revenue RMB 2,917.7 Million
THOMSON REUTERS  ·  08-18
Giant Biogene Holding H1 Revenue RMB 2,917.7 Million
Movement Alert｜GIANT BIOGENE Declines 5.51% in Regular Trading, HK Personal Products Sector Faces Broad Selloff on Peer Profit Warning
Market Focus  ·  08-18
Movement Alert｜GIANT BIOGENE Declines 5.51% in Regular Trading, HK Personal Products Sector Faces Broad Selloff on Peer Profit Warning
Earning Preview: GIANT BIOGENE this quarter’s revenue is expected to increase by 0%, and institutional views are bullish
Earnings Agent  ·  08-11
Earning Preview: GIANT BIOGENE this quarter’s revenue is expected to increase by 0%, and institutional views are bullish
Giant Biogene Sets 18 Aug 2026 Board Meeting to Review 1H26 Results and Potential Interim Dividend
Bulletin Express  ·  08-05
Giant Biogene Sets 18 Aug 2026 Board Meeting to Review 1H26 Results and Potential Interim Dividend
Giant Biogene Schedules Board Meeting to Review Interim Results, Consider Dividend
Reuters  ·  08-05
Giant Biogene Schedules Board Meeting to Review Interim Results, Consider Dividend
Giant Biogene Maintains Stable Share Capital and Confirms Public Float Compliance in July 2026 Return
Bulletin Express  ·  08-04
Giant Biogene Maintains Stable Share Capital and Confirms Public Float Compliance in July 2026 Return
Movement Alert｜GIANT BIOGENE Rises 5.54% in Regular Trading, HK New Consumption Sector Rally Combined with Medical Aesthetics Expansion
Market Focus  ·  07-29
Movement Alert｜GIANT BIOGENE Rises 5.54% in Regular Trading, HK New Consumption Sector Rally Combined with Medical Aesthetics Expansion
Jefferies Adjusts Giant Biogene's Price Target to HK$32 From HK$35, Keeps at Hold
MT Newswires Live  ·  07-20
Jefferies Adjusts Giant Biogene's Price Target to HK$32 From HK$35, Keeps at Hold

Introduction

Company Name.
GIANT BIOGENE
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Giant Biogene Holding Co Ltd is an investment holding company primarily engaged in the research, development, manufacture and sale of bioactive material-based beauty and health products. The Company's main products include professional skin treatment products such as functional skincare products and medical dressings, as well as functional foods and others. The Company primarily conducts its businesses in domestic market.
Issue price:
--